By Linda Chiem ( February 21, 2013, 6:59 PM EST) -- Teva Pharmaceutical Industries Ltd. said its patent for its Parkinson's disease drug Azilect is valid and would-be generic competitors are overreaching in claims that it broke antitrust laws to secure the patent through fraud and sham suits, according to a pretrial brief filed Wednesday in New Jersey federal court....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.